Teyssier J R, Bénard J, Ferre D, Da Silva J, Renaud L
Laboratoire d'Histologie-Embryologie-Cytogénétique. INSERM U 314, Faculté de Médecine, Reims, France.
Cancer Genet Cytogenet. 1989 May;39(1):35-43. doi: 10.1016/0165-4608(89)90227-6.
Four resistant sublines were derived from the sensitive human ovarian carcinoma IGROV 1 (OV1-P) cell line by exposure to increasing concentrations of vincristine, doxorubicin, and cisplatinum. The vincristine-resistant sublines expressed the MDR phenotype associated with a complete reversion of malignant properties. Cytogenetic studies of sensitive and resistant cells have been repeatedly performed over a 1-year period. Consistent and stable drug-related chromosomal structural rearrangements have been observed in each resistant population affecting chromosomes 3, 4, 6, 8, 11, 22, and X. The most significant result was the presence in OV1/P cells of a minor subclone with a del(11)(p13) marker that represented the whole OV1/VCR population. This result suggests a possible role of this deletion either in the drug-selection process, or in the malignant reversion.
通过暴露于浓度逐渐增加的长春新碱、阿霉素和顺铂，从敏感的人卵巢癌IGROV 1（OV1-P）细胞系中获得了四个耐药亚系。长春新碱耐药亚系表现出与恶性特性完全逆转相关的多药耐药（MDR）表型。在1年的时间里，对敏感细胞和耐药细胞进行了多次细胞遗传学研究。在每个耐药群体中均观察到一致且稳定的与药物相关的染色体结构重排，涉及3号、4号、6号、8号、11号、22号染色体和X染色体。最显著的结果是在OV1/P细胞中存在一个带有del(11)(p13)标记的小亚克隆，该亚克隆代表了整个OV1/VCR群体。这一结果表明该缺失可能在药物选择过程或恶性逆转中发挥作用。
